Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has said Events
Scientists and doctors remain divided on the targeted antibody drugs that slow down the early stages of Alzheimer’s Events
Two drugs – donanemab and lecanemab – have been rejected for NHS use because their benefits are "too small" to justify their cost Events
Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s. Events
The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use on the NHS as they are too expensive to justify. Events
Austerity-era scepticism runs deep – and Labour’s abstract promises are falling flat as Nigel Farage rises in the pollsThe Labour government’s abrupt U-turn on winter fuel payments – restoring the benefit to more than three-quarters of pensioners – reveals less a change of heart than a sobering realisation in Westminster: after years of austerity, the public no longer gives politicians the benefit of the doubt. The irony is hard to miss. Labour set out to prove that “grown-up” economics means difficult decisions – only to find that once trust is lost, voters won’t accept vague promises without tangible results.It turns out many are sceptical that sacrifices will produce better results for society. That’s why ministers are struggling to justify cuts to disability benefits as a way to “fund” public services – or to convince the public that Britain can’t afford to lift the two-child benefit cap even as ministers claim they will reduce child poverty. There may be more conspicuous retrea... Politics
The new review of Alzheimer’s disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs. Events
Experts say more than 100 potential dementia drugs could one day be used to "slow and ultimately stop" Alzheimer's disease Events
A third of the drugs that are currently being trialled are 'repurposed' medications that are already being used to tackle other diseases, including diabetes and multiple sclerosis Politics
There has been an 11% increase in the number of clinical trials assessing potential treatments. Events
